Abstract:Off-target inhibition of the human cardiac sodium channel (hNav1.5) can prolong the QRS interval and has been associated with increased mortality in patients with underlying cardiovascular diseases. Given the cardiac safety implications for patients and the costs of late stage drug development, detection and mitigation of hNav1.5 liabilities early in drug discovery and development is critically important. Cardiac Na channel activities are typically tested using in vitro methods i.e. patch clamp in transfected cells, followed by in vivo evaluation. Two classes of compounds showed dose-dependent QRS prolongation in the dog telemetry studies despite little in vitro activity on Nav1.5 (Compound 1, up to 100 μM) or weak activity (Compound 2) with IC50 of 46 μM) in a patch clamp assay. Putatively a more predictive in vitro assay for detecting Nav1.5 inhibition, a rabbit ventricular wedge (RVW) was used given its sensitivity for detecting Nav1.5 activity. Methods and Results: Jacket telemetry was used to record surface ECG’s in beagle dogs (n=3). The wedge preparations (n=4, male, New Zealand White rabbits) were perfused with Tyrode’s solution via the coronary artery in a tissue bath. The dog findings demonstrated a dosedependent increase in QRS intervals after administration of compound 1 or 2. The RVW indicated both compound 1 and 2 produced a concentration-dependent increase in QRS duration and loss of excitation at 100 μM for compound 2, indicative of inward Na current (INa) inhibition. Both compounds prolonged QRS duration in a usedependent manner. Conclusions: The RVW reliably detects cardiac Na channel blockade in a use-dependent manner, but that had tested negative on Nav1.5 patch clamp tests. Thus, the rabbit wedge assay can be used to detect Nav1.5 blockade, and is a valuable addition to be incorporated in early testing.

Application of an in Vitro Model for Early Detection of Cardiac Sodium Channel Blocking Liabilities